Viewing Study NCT05202808

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 10:56 AM
Ignite Modification Date: 2026-01-01 @ 6:32 AM
Study NCT ID: NCT05202808
Status: COMPLETED
Last Update Posted: 2025-04-20
First Post: 2021-12-29
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study
Sponsor:
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Raw JSON

{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2025-03-25', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D001035', 'term': 'Aphakia'}, {'id': 'D002386', 'term': 'Cataract'}], 'ancestors': [{'id': 'D007905', 'term': 'Lens Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'dgoffredo@rxsight.com', 'phone': '9494215463', 'title': 'Director, Clinical Trials', 'phoneExt': '300', 'organization': 'RxSight, Inc.'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '6 months', 'description': 'Non-serious, ocular AEs are being reported for study eyes only.', 'eventGroups': [{'id': 'EG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments', 'otherNumAtRisk': 335, 'deathsNumAtRisk': 335, 'otherNumAffected': 71, 'seriousNumAtRisk': 335, 'deathsNumAffected': 0, 'seriousNumAffected': 7}, {'id': 'EG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL', 'otherNumAtRisk': 165, 'deathsNumAtRisk': 165, 'otherNumAffected': 26, 'seriousNumAtRisk': 165, 'deathsNumAffected': 0, 'seriousNumAffected': 2}], 'otherEvents': [{'term': 'Allergic Conjunctivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Amaurosis Fugax', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Anterior Chamber Inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 7, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 7, 'numAffected': 6}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blepharoplasty', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blurry Vision', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Clinically significant cystoid macular edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Conjunctival Cyst', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Corneal Abrasion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cystoid Macular Edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'De-centered optic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dot Hemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Epithelial Defect', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypertensive Retinopathy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Iritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Keratoconjunctivitis Sicca, not specified as Sjogrens', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Corneal Erosion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Corneal Edema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Conjunctivochalasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Conjunctivitis Medicamentosa', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Conjunctival Hyperemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Visual Symptoms due to Concussion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dot Hemorrhages and Microaneurysms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dry Eye', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dry Eye Syndrome', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Epiretinal Membrane', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Epithelial Basement Membrane Dystrophy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Erythropsia score 2 (red) any time after Week 3 or Erythropsia score 1 (pink) or 2 (red) at Month 6', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Floaters', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hordeolum', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Light Treatment Sensitivity', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Loss of BCDVA of >= 10 letters (when compared to Preop and/or Postop Week 3 BCDVA)', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Meibomian Gland Dysfunction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Ocular Allergies', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Ocular Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Posterior Capsular tear', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Posterior Vitreous Detachment', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 3, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Raised IOP', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 14, 'numAffected': 14}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Raised IOP >=10 mmHg above preop & >=25 mmHg (if present > Week 1), unrelated to mech. pupil. block', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 3, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Rebound Iritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Retinal Hole', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Retinal Microaneurysm', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Subconjunctival Abrasion with Hemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Superficial Punctate Keratitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 16, 'numAffected': 16}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Uveitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Wound leak', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Secondary Surgical Intervention: Intraocular Lens Exchange', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Secondary Surgical Intervention: Iris Repositioning following prolapse', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Secondary Surgical Intervention: Study Eye, Selective Laser Trabeculoplasty', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Secondary Surgical Intervention: Non-Study Eye Intraocular Lens Exchange', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Non-Study Eye, Full Thickness Macular Hole', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Secondary Surgical Intervention: Non-Study Eye, Macular Hole Repair', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Inpatient hospitalization following Hip Replacement Surgery', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Inpatient hospitalization for Ventral Hernia Repair Surgery', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Inpatient hospitalization due to Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Inpatient hospitalization due to Salmonella Infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Inpatient hospitalization due to Obstruction of Gallbladder', 'stats': [{'groupId': 'EG000', 'numAtRisk': 335, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 165, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Surgical and medical procedures', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Absolute Manifest Refraction Spherical Equivalent (MRSE) Compared Between the Two Study Groups, LAL and Control', 'denoms': [{'units': 'Participants', 'counts': [{'value': '332', 'groupId': 'OG000'}, {'value': '164', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'OG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'classes': [{'categories': [{'measurements': [{'value': '0.210', 'spread': '0.213', 'groupId': 'OG000'}, {'value': '0.345', 'spread': '0.265', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Postop Month 6', 'unitOfMeasure': 'Diopters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Absolute Manifest Cylinder (MRCYL) Compared Between the Two Study Groups, LAL and Control', 'denoms': [{'units': 'Participants', 'counts': [{'value': '332', 'groupId': 'OG000'}, {'value': '164', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'OG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'classes': [{'categories': [{'measurements': [{'value': '0.262', 'spread': '0.275', 'groupId': 'OG000'}, {'value': '0.820', 'spread': '0.554', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Postop Month 6', 'unitOfMeasure': 'Diopters', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Rate of Endothelial Cell Density Loss', 'denoms': [{'units': 'Participants', 'counts': [{'value': '185', 'groupId': 'OG000'}, {'value': '97', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'OG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'classes': [{'categories': [{'measurements': [{'value': '5.1', 'groupId': 'OG000', 'lowerLimit': '3.8', 'upperLimit': '7.0'}, {'value': '4.9', 'groupId': 'OG001', 'lowerLimit': '3.0', 'upperLimit': '6.5'}]}]}], 'analyses': [{'pValue': '<0.0001', 'groupIds': ['OG000', 'OG001'], 'paramType': 'Median Difference (Final Values)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '90', 'paramValue': '0.2', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '1.66', 'groupDescription': 'With a one-sided significance level of 0.05, a power of 0.80, a randomization ratio of 2:1, and then the Mann-Whitney-Wilcoxon asymptotic relative efficiency (A.R.E.) efficiency adjustment, the sample size per two-sample t-test is 192 LAL eyes and 96 Control eyes (total of 288), with an assumed dropout rate of 10%.', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'NON_INFERIORITY', 'nonInferiorityComment': 'The endothelial cell loss (ECL) at 6 months was compared between the LAL and Control groups. The statistical hypothesis is:\n\n* H0: Median(LAL) - Median(control) ≥ 5% vs\n* Ha: Median(LAL) - Median(control) \\< 5%\n\nThe median ECL for the LAL group is at most 5% higher than the median ECL for the Control group.\n\nThe first co-primary safety endpoint is met if the median ECL of the LAL group is non-inferior to the Control group using a right-tail Wilcoxon test using a significance level of 0.05.'}], 'paramType': 'MEDIAN', 'timeFrame': 'Postop Month 6', 'description': 'The median difference was compared against a 5% non-inferiority margin for endothelial cell density loss using a right-tail Mann-Whitney-Wilcoxon test with a significance level of 0.05.', 'unitOfMeasure': 'percentage Endothelial Cell Change', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Rate of Retinal Findings', 'denoms': [{'units': 'Participants', 'counts': [{'value': '331', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Postop Month 6', 'description': 'Rate of retinal findings in the Light adjustable lens (LAL) and Light Delivery Device (LDD) treatment group only.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'Odds and Odds Ratio of Achieving Uncorrected Distance Visual Acuity (UCDVA) 20/20 or Better at Postop Month 6 Compared Between the RxSight LAL and Control Group', 'denoms': [{'units': 'Participants', 'counts': [{'value': '332', 'groupId': 'OG000'}, {'value': '164', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'OG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'classes': [{'categories': [{'title': 'UCDVA 20/20 or better', 'measurements': [{'value': '274', 'groupId': 'OG000'}, {'value': '83', 'groupId': 'OG001'}]}, {'title': 'UCDVA worse than 20/20', 'measurements': [{'value': '58', 'groupId': 'OG000'}, {'value': '81', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '4.61', 'ciLowerLimit': '2.97', 'ciUpperLimit': '7.15', 'estimateComment': 'Light adjustable lens (LAL) and Light Delivery Device (LDD) group is the numerator and Control group is the denominator. At Month 6, the odds of achieving UCDVA of 20/20 or better were 4.61 times greater for the LAL group than the Control group.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '6 months', 'description': 'Success defined as UCDVA 20/20 or better, failure defined as UCDVA worse than 20/20. Odds defined as number of successes divided by number of failures.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'Odds and Odds Ratio of Achieving 0.5 Diopters or Less of Absolute MRCYL Compared Between the RxSight LAL and Control Group', 'denoms': [{'units': 'Participants', 'counts': [{'value': '332', 'groupId': 'OG000'}, {'value': '164', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'OG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'classes': [{'categories': [{'title': 'Absolute MRCYL 0.50 D or less', 'measurements': [{'value': '307', 'groupId': 'OG000'}, {'value': '61', 'groupId': 'OG001'}]}, {'title': 'Absolute MCRYL worse than 0.50 D', 'measurements': [{'value': '25', 'groupId': 'OG000'}, {'value': '103', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '20.74', 'ciLowerLimit': '12.05', 'ciUpperLimit': '36.14', 'estimateComment': 'Light adjustable lens (LAL) and Light Delivery Device (LDD) group is the numerator and the Control group is the denominator. The odds of achieving Absolute MRCYL of 0.5D or less was 20.74 for the LAL group versus the Control group at month 6.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '6 months', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'POST_HOC', 'title': 'Odds and Odds Ratio of Achieving Simultaneous Absolute Manifest Refraction Spherical Equivalent (MRSE) and Absolute Manifest Cylinder (MRCYL) of 0.50 D or Less at Postop Month 6 Compared Between the RxSight LAL and Control Group', 'denoms': [{'units': 'Participants', 'counts': [{'value': '332', 'groupId': 'OG000'}, {'value': '164', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'OG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'classes': [{'categories': [{'title': 'Simultaneous absolute MRSE and absolute MRCYL of 0.50 D or less', 'measurements': [{'value': '291', 'groupId': 'OG000'}, {'value': '54', 'groupId': 'OG001'}]}, {'title': 'Simultaneous absolute MRSE and absolute MRCYL worse than 0.50 D', 'measurements': [{'value': '41', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'paramType': 'Odds Ratio (OR)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '14.46', 'ciLowerLimit': '8.89', 'ciUpperLimit': '23.57', 'estimateComment': 'Light adjustable lens (LAL) and Light Delivery Device (LDD) group is the numerator and the Control group is the denominator. The odds of achieving simultaneous Absolute MRSE and MRCL of 0.5 D or less was 14.46 in the LAL group vs. Control at month 6.', 'nonInferiorityType': 'OTHER'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '6 months', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'FG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numUnits': '335', 'numSubjects': '335'}, {'groupId': 'FG001', 'numUnits': '165', 'numSubjects': '165'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '332', 'numSubjects': '332'}, {'groupId': 'FG001', 'numUnits': '164', 'numSubjects': '164'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numUnits': '3', 'numSubjects': '3'}, {'groupId': 'FG001', 'numUnits': '1', 'numSubjects': '1'}]}], 'dropWithdraws': [{'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}], 'typeUnitsAnalyzed': 'Eyes'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '335', 'groupId': 'BG000'}, {'value': '165', 'groupId': 'BG001'}, {'value': '500', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Light Adjustable Lens (LAL) and Light Delivery Device (LDD)', 'description': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD): Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments'}, {'id': 'BG001', 'title': 'Control IOL', 'description': 'Control IOL: Control treatment group will receive a Control IOL'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '67.3', 'spread': '6.9', 'groupId': 'BG000'}, {'value': '67.1', 'spread': '6.3', 'groupId': 'BG001'}, {'value': '67.1', 'spread': '6.8', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '227', 'groupId': 'BG000'}, {'value': '106', 'groupId': 'BG001'}, {'value': '333', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '108', 'groupId': 'BG000'}, {'value': '59', 'groupId': 'BG001'}, {'value': '167', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'American Indian or Alaska Native', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}]}, {'title': 'Asian', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}]}]}, {'title': 'Black or African American', 'categories': [{'measurements': [{'value': '23', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}]}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}, {'title': 'Caucasian', 'categories': [{'measurements': [{'value': '305', 'groupId': 'BG000'}, {'value': '156', 'groupId': 'BG001'}, {'value': '461', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '335', 'groupId': 'BG000'}, {'value': '165', 'groupId': 'BG001'}, {'value': '500', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-01-20', 'size': 1800172, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2025-02-25T19:32', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Subjects will be randomized 2:1 to undergo experimental or control treatment.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 500}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-12-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2024-12-16', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-17', 'studyFirstSubmitDate': '2021-12-29', 'resultsFirstSubmitDate': '2025-02-25', 'studyFirstSubmitQcDate': '2022-01-18', 'lastUpdatePostDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2025-04-17', 'studyFirstPostDateStruct': {'date': '2022-01-24', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2025-04-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-09-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Absolute Manifest Refraction Spherical Equivalent (MRSE) Compared Between the Two Study Groups, LAL and Control', 'timeFrame': 'Postop Month 6'}, {'measure': 'Absolute Manifest Cylinder (MRCYL) Compared Between the Two Study Groups, LAL and Control', 'timeFrame': 'Postop Month 6'}], 'secondaryOutcomes': [{'measure': 'Rate of Endothelial Cell Density Loss', 'timeFrame': 'Postop Month 6', 'description': 'The median difference was compared against a 5% non-inferiority margin for endothelial cell density loss using a right-tail Mann-Whitney-Wilcoxon test with a significance level of 0.05.'}, {'measure': 'Rate of Retinal Findings', 'timeFrame': 'Postop Month 6', 'description': 'Rate of retinal findings in the Light adjustable lens (LAL) and Light Delivery Device (LDD) treatment group only.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'keywords': ['Light Adjustable Lens', 'LAL', 'Intraocular lens'], 'conditions': ['Aphakia', 'Cataract']}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to conduct a post-approval study which compares the LAL to a monofocal control IOL for safety outcomes.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '40 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Must sign a written Informed Consent form and be willing to undergo cataract surgery for the implantation of an IOL with random assignment to either the RxSight LAL or the monofocal control IOL.\n* Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.\n* Willing and able to comply with the requirements for study specific procedures and visits.\n* Able to complete a written questionnaire in English.\n\nExclusion Criteria:\n\n* Pre-existing macular disease in either eye.\n* Patients with sufficiently dense cataracts that preclude examination of the macula in either eye.\n* History of uveitis in either eye.\n* Evidence of ectasia in either eye.\n* Previous intraocular surgery in either eye. Eyes with previous pterygium excision are permitted as long as the pterygium did not extend more than 2mm onto the cornea from the limbus.\n* Subjects taking systemic medication that may increase sensitivity to UV light.\n* Subjects taking a systemic medication that is considered toxic to the retina such as tamoxifen.\n* History of ocular herpes simplex virus in either eye.'}, 'identificationModule': {'nctId': 'NCT05202808', 'briefTitle': 'RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study', 'organization': {'class': 'INDUSTRY', 'fullName': 'RxSight, Inc.'}, 'officialTitle': 'RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study', 'orgStudyIdInfo': {'id': 'CSP-029'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Light adjustable lens (LAL) and Light Delivery Device (LDD)', 'interventionNames': ['Device: Light Adjustable lens (LAL) and Light Delivery Device (LDD)']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Control IOL', 'interventionNames': ['Device: Control IOL']}], 'interventions': [{'name': 'Light Adjustable lens (LAL) and Light Delivery Device (LDD)', 'type': 'DEVICE', 'description': 'Experimental treatment group will receive Light adjustable lens with Light delivery Device treatments', 'armGroupLabels': ['Light adjustable lens (LAL) and Light Delivery Device (LDD)']}, {'name': 'Control IOL', 'type': 'DEVICE', 'description': 'Control treatment group will receive a Control IOL', 'armGroupLabels': ['Control IOL']}]}, 'contactsLocationsModule': {'locations': [{'zip': '72704', 'city': 'Fayetteville', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Vold Vision', 'geoPoint': {'lat': 36.06258, 'lon': -94.15743}}, {'zip': '95926', 'city': 'Chico', 'state': 'California', 'country': 'United States', 'facility': 'Reeve Woods Eye Center', 'geoPoint': {'lat': 39.72849, 'lon': -121.83748}}, {'zip': '33770', 'city': 'Largo', 'state': 'Florida', 'country': 'United States', 'facility': 'The Eye Institute of West Florida', 'geoPoint': {'lat': 27.90979, 'lon': -82.78842}}, {'zip': '33870', 'city': 'Sebring', 'state': 'Florida', 'country': 'United States', 'facility': 'Newsom Eye', 'geoPoint': {'lat': 27.49559, 'lon': -81.44091}}, {'zip': '56308', 'city': 'Alexandria', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Vance Thompson Vision', 'geoPoint': {'lat': 45.88524, 'lon': -95.37754}}, {'zip': '68137', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Vance Thompson Vision', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '89145', 'city': 'Las Vegas', 'state': 'Nevada', 'country': 'United States', 'facility': 'Center for Sight', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '44141', 'city': 'Brecksville', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland Eye Clinic', 'geoPoint': {'lat': 41.31978, 'lon': -81.62679}}, {'zip': '29464', 'city': 'Mt. Pleasant', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Carolina Eyecare Physicians, LLC', 'geoPoint': {'lat': 32.79407, 'lon': -79.86259}}, {'zip': '57108', 'city': 'Sioux Falls', 'state': 'South Dakota', 'country': 'United States', 'facility': 'Vance Thompson Vision Clinic', 'geoPoint': {'lat': 43.54369, 'lon': -96.72796}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Key-Whitman Eye Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77027', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Slade &amp; Baker Vision', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '76054', 'city': 'Hurst', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Eye Research Center', 'geoPoint': {'lat': 32.82346, 'lon': -97.17057}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Focal Point Vision', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'RxSight, Inc.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}